MXPA05009384A - Procedimiento para la preparacion de derivados de topiramato anticonvulsivos. - Google Patents

Procedimiento para la preparacion de derivados de topiramato anticonvulsivos.

Info

Publication number
MXPA05009384A
MXPA05009384A MXPA05009384A MXPA05009384A MXPA05009384A MX PA05009384 A MXPA05009384 A MX PA05009384A MX PA05009384 A MXPA05009384 A MX PA05009384A MX PA05009384 A MXPA05009384 A MX PA05009384A MX PA05009384 A MXPA05009384 A MX PA05009384A
Authority
MX
Mexico
Prior art keywords
preparation
topiramate
anticonvulsant derivatives
derivatives
anticonvulsant
Prior art date
Application number
MXPA05009384A
Other languages
English (en)
Inventor
John Mills
Original Assignee
Johnson & Johnson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson filed Critical Johnson & Johnson
Publication of MXPA05009384A publication Critical patent/MXPA05009384A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/02—Monoamides of sulfuric acids or esters thereof, e.g. sulfamic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
    • C07H9/04—Cyclic acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/04—Diamides of sulfuric acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente invencion se dirige a un procedimiento de un paso para la preparacion de derivados de sulfamato de fructopiranosa de la formula general (I) (ver formula general (I)), en donde, X, R1, R3, R4, R5 Y R6 son como se describen en la especificacion.
MXPA05009384A 2003-03-04 2004-03-02 Procedimiento para la preparacion de derivados de topiramato anticonvulsivos. MXPA05009384A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45186303P 2003-03-04 2003-03-04
PCT/US2004/006263 WO2004078769A1 (en) 2003-03-04 2004-03-02 Process for the preparation of anticonvulsant derivatives of topiramate

Publications (1)

Publication Number Publication Date
MXPA05009384A true MXPA05009384A (es) 2006-02-28

Family

ID=32962650

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05009384A MXPA05009384A (es) 2003-03-04 2004-03-02 Procedimiento para la preparacion de derivados de topiramato anticonvulsivos.

Country Status (27)

Country Link
US (1) US7157589B2 (es)
EP (1) EP1599490B8 (es)
JP (1) JP4725976B2 (es)
KR (1) KR20050119111A (es)
CN (1) CN100376591C (es)
AR (1) AR043466A1 (es)
AT (1) ATE421521T1 (es)
AU (1) AU2004217974A1 (es)
BR (1) BRPI0407967A (es)
CA (1) CA2517964A1 (es)
CL (1) CL2004000438A1 (es)
DE (1) DE602004019191D1 (es)
DK (1) DK1599490T3 (es)
ES (1) ES2254047T3 (es)
HK (1) HK1088336A1 (es)
HR (1) HRP20050756A2 (es)
MX (1) MXPA05009384A (es)
MY (1) MY139235A (es)
NO (1) NO20054538L (es)
NZ (1) NZ541811A (es)
PT (1) PT1599490E (es)
RU (1) RU2333216C2 (es)
SI (1) SI1599490T1 (es)
TW (1) TW200504089A (es)
UA (1) UA81657C2 (es)
WO (1) WO2004078769A1 (es)
ZA (1) ZA200507995B (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7638291B2 (en) * 2004-10-25 2009-12-29 Seradyn, Inc. Immunoassays for topiramate
US20060088886A1 (en) * 2004-10-25 2006-04-27 Anlong Ouyang Topiramate analogs
WO2007099388A1 (en) * 2006-03-01 2007-09-07 Glade Organics Private Limited An improved process for the manufacture of topiramate
WO2008010231A2 (en) * 2006-05-26 2008-01-24 Alembic Limited A process for the purification of topiramate
US20090076128A1 (en) * 2007-09-15 2009-03-19 Protia Llc Deuterium-enriched topiramate
US9303038B2 (en) 2011-09-06 2016-04-05 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological diseases
EP2847169A4 (en) 2012-05-07 2015-09-30 Cellix Bio Private Ltd COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS
AU2013257742A1 (en) 2012-05-07 2014-11-27 Cellixbio Private Limited Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
WO2013167993A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological degenerative disorders
WO2013167992A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of inflammatory disorders
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
SG11201407318UA (en) 2012-05-10 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of metabolic syndrome
WO2013168011A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of chronic pain
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
WO2013168001A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
US9315478B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
JP2015518855A (ja) 2012-05-23 2015-07-06 セリックスビオ プライヴェート リミテッド 粘膜炎の治療のための組成物および方法
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
EP2852569B1 (en) 2012-05-23 2020-10-14 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
WO2013175347A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
WO2013175357A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of inflammatory bowel disease
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
SG11201407325YA (en) 2012-09-08 2014-12-30 Cellix Bio Private Ltd Compositions and methods for treatment of inflammation and lipid disorders
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
CA2914461A1 (en) 2013-06-04 2014-12-11 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
CA2976314C (en) 2014-09-26 2021-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
CA2967908C (en) 2014-09-29 2020-11-17 Mahesh Kandula Compositions and methods for the treatment of multiple sclerosis
WO2016098119A1 (en) 2014-10-27 2016-06-23 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
ES2905771T3 (es) 2015-01-06 2022-04-12 Cellix Bio Private Ltd Composiciones y procedimientos para el tratamiento de la inflamación y del dolor
CN106632530A (zh) * 2016-12-08 2017-05-10 陕西大生制药科技有限公司 高纯度托吡酯的制备方法
CN108341844A (zh) * 2018-04-25 2018-07-31 广州小桔生物科技有限公司 一种高纯度托吡酯的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582916A (en) 1983-09-26 1986-04-15 Mcneilab, Inc. Chlorosulfate and azidosulfate esters of tetrahydro-2H-pyran-2-yl-methanol
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
IL103172A (en) 1991-09-19 1997-01-10 Mcneilab Inc Preparation of chlorosulfate and sulfamate derivatives of 2, 3:4, 5-bis-o-(1-methylethylidene)-beta-d-fructopyranose and (1-methylcyclohexyl) methanol

Also Published As

Publication number Publication date
RU2005127626A (ru) 2006-01-27
CN1756760A (zh) 2006-04-05
RU2333216C2 (ru) 2008-09-10
MY139235A (en) 2009-09-30
JP2006519860A (ja) 2006-08-31
NZ541811A (en) 2008-07-31
CL2004000438A1 (es) 2005-01-21
US20040215004A1 (en) 2004-10-28
HK1088336A1 (en) 2006-11-03
US7157589B2 (en) 2007-01-02
KR20050119111A (ko) 2005-12-20
CN100376591C (zh) 2008-03-26
DK1599490T3 (da) 2009-04-27
ES2254047T3 (es) 2009-05-14
JP4725976B2 (ja) 2011-07-13
ATE421521T1 (de) 2009-02-15
CA2517964A1 (en) 2004-09-16
EP1599490B1 (en) 2009-01-21
UA81657C2 (ru) 2008-01-25
WO2004078769A1 (en) 2004-09-16
NO20054538L (no) 2005-10-03
TW200504089A (en) 2005-02-01
AU2004217974A1 (en) 2004-09-16
HRP20050756A2 (en) 2006-07-31
ZA200507995B (en) 2007-01-31
PT1599490E (pt) 2009-04-03
BRPI0407967A (pt) 2006-03-07
ES2254047T1 (es) 2006-06-16
SI1599490T1 (sl) 2009-06-30
EP1599490B8 (en) 2009-04-08
EP1599490A1 (en) 2005-11-30
AR043466A1 (es) 2005-07-27
DE602004019191D1 (de) 2009-03-12

Similar Documents

Publication Publication Date Title
MXPA05009384A (es) Procedimiento para la preparacion de derivados de topiramato anticonvulsivos.
WO2003097656A3 (en) Novel substituted sulfamate anticonvulsant derivatives
MY133392A (en) Novel substituted pyrazole derivatives
WO2002098865A3 (fr) Inhibiteurs des phosphodiesterases des nucleotides cycliques, preparation et utilisations de ces inhibiteurs
MY138478A (en) Benzazepine derivatives for the treatment of neurological disorders
YU91002A (sh) Derivati acilfenil-karbamida, postupak za njihovu proizvodnju i njihova primena kao leka
RS20100100A (en) Xantine derivatives, production and use thereof as a medicament
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
HK1089444A1 (en) Dihydropteridinones, method for the production and use thereof in the form of drugs
TWI256951B (en) Thiazolyl amide derivatives
DE59800935D1 (en) Immuntolerante prothrombinkomplex-präparation
IL150061A0 (en) Purine derivatives
AP2001002306A0 (en) Bridged piperazine derivatives.
UA66866C2 (uk) Синтез морфолінових похідних
BG105766A (en) New process for preparing pesticidal intermediates
MY137066A (en) Continuous process for the preparation of fructopyranose sulfamate derivatives
TW200510448A (en) Novel process and intermediates for preparing 17-halogenated 19-norsteroid compounds
IL148161A0 (en) Process for the preparation of 2-cyanopyridines
MXPA05003881A (es) Preparacion de compuestos triazospiro.
ECSP003761A (es) Compuestos heterociclicos sililados
MXPA03003466A (es) Derivados de piranosido.
MXPA04001852A (es) Uso de sistemas indan-1-ol c2-sustituidas para la produccion de medicamentos para la profilaxis o tratamiento de obesidad.
MXPA04001856A (es) Indan-1-oles c2-sustituidos y sus derivados, metodo para su produccion y su uso como medicamentos.
MXPA04001846A (es) Indan-1-onas c2-substituidas y sus derivados, metodos para su produccion y su uso como medicamentos.
MXPA03008727A (es) Procedimiento para la preparacion de derivados de imidazol tetrasubstituidos y estructuras cristalinas novedosas de los mismos.

Legal Events

Date Code Title Description
FG Grant or registration